Jazz Pharmaceuticals Q2 2021 Earnings Report
Key Takeaways
Jazz Pharmaceuticals announced a 34% increase in total revenues to $751.8 million compared to the second quarter of 2020. The company reaffirmed its 2021 total revenue guidance at $3.02 billion to $3.18 billion.
Closed GW Pharmaceuticals plc Acquisition, Creating an Innovative, High-Growth, Global Biopharma Leader
41% of Net Product Sales from Recently Launched or Acquired Products
Strong Xywavâ„¢ Adoption with 5,100 Active Patients Exiting the Second Quarter
FDA Approval and Launch of Rylazeâ„¢ in the U.S.
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Jazz Pharmaceuticals Revenue by Segment
Forward Guidance
Jazz Pharmaceuticals is reaffirming its previously communicated full year 2021 non-GAAP financial guidance and updating its 2021 GAAP guidance. This guidance reflects the Company's current and future expected operational performance, including COVID-19 related impacts, the strength of its underlying operations and the prioritization of new and ongoing value creating development projects.